2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

4:30PM-6:00PM: Abstract Number: 2106

Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014

Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization

4:30PM-6:00PM: Abstract Number: 2115

Intra-Operative Synovitis Predicts Worse Pain and Function 2 Years after Total Knee Arthroplasty for Osteoarthritis

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2145

Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA

4:30PM-6:00PM: Abstract Number: 2092

Knee Pain Burden Is Associated with Decreased Moderate to Vigorous Physical Activity: Data from the Osteoarthritis Initiative

Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA

4:30PM-6:00PM: Abstract Number: 2113

Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout

Metabolic and Crystal Arthropathies I: Therapeutics

4:30PM-6:00PM: Abstract Number: 2152

Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2169

Low Education Is Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project

ARHP III: Epidemiology and Public Health

4:30PM-6:00PM: Abstract Number: 2134

Metabolic Reprogramming in the Inflamed Joint Inhibits Pro-Inflammatory Mechanisms

Rheumatoid Arthritis - Human Etiology and Pathogenesis II

4:30PM-6:00PM: Abstract Number: 2135

miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation

Rheumatoid Arthritis - Human Etiology and Pathogenesis II

4:30PM-6:00PM: Abstract Number: 2132

Monocarboxylate Transporter 4, Associated with the Acidification of Synovial Fluid, Is a Novel Therapeutic Target for Inflammatory Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis II

4:30PM-6:00PM: Abstract Number: 2158

Mortality Associated with Giant Cell Arteritis from 1980 to 2011: An Analysis of the French National Death Certificate Database

Vasculitis II

4:30PM-6:00PM: Abstract Number: 2089

Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions

Biology and Pathology of Bone and Joint: Bone Remodeling

4:30PM-6:00PM: Abstract Number: 2153

Nintedanib Ameliorates Fibrotic and Vascular Manifestations in Preclinical Models of Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2121

Placentas of Lupus Pregnancies Are Characterized By Marked Inflammatory Changes Despite Good Disease Control

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects

4:30PM-6:00PM: Abstract Number: 2118

Prescription Medication Use in Community-Based US Adults with Chronic Low Back Pain: Nhanes 2009-2010

Orthopedics, Low Back Pain and Rehabilitation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].